WO2004070046A1 - 糖鎖アスパラギン誘導体の製造方法 - Google Patents
糖鎖アスパラギン誘導体の製造方法 Download PDFInfo
- Publication number
- WO2004070046A1 WO2004070046A1 PCT/JP2004/001048 JP2004001048W WO2004070046A1 WO 2004070046 A1 WO2004070046 A1 WO 2004070046A1 JP 2004001048 W JP2004001048 W JP 2004001048W WO 2004070046 A1 WO2004070046 A1 WO 2004070046A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sugar chain
- chain asparagine
- derivative
- producing
- sugar
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the present invention relates to a method for producing a sugar chain asparagine derivative.
- nucleic acid DNA
- third chain life molecules following proteins.
- the human body is a large cell society consisting of approximately 60 trillion cells, and all cell surfaces are covered with sugar chain molecules.
- a B O blood group is determined by the difference in sugar chains on the cell surface.
- Sugar chains have a role in recognition and interaction between cells, and are the key to the establishment of a cellular society. Disruption of the cellular society can lead to cancer, chronic diseases, infectious diseases, and aging.
- Sugar chains are very complex structures compared to the structures of nucleic acids and proteins, due to the diversity of monosaccharide sequences, binding patterns, sites, chain lengths, branching patterns, and overall higher-order structures. Therefore, biological information derived from the structure is more diverse than nucleic acids and proteins. Although the importance of research is recognized for sugar chains, the progress of research is delayed compared to nucleic acids and proteins due to the complexity and diversity of their structures.
- sugar chain asparagine can be obtained from defatted egg yolk (see, for example, Patent Document 1).
- sugar chain asparagine is obtained in a larger amount than before by adding almond or apricot seeds to defatted egg yolk.
- the sugar chain asparagine obtained by this method has a purity of 95% or 92%, and it cannot be said that a pure sugar chain asparagine has been isolated. Yield is also 29.5 g or 27.2 g of disialyloligosaccharide (11-sugar disialyloligosaccharide) from 100 kg of defatted egg yolk.
- sugar chain asparagine can be obtained from a glycopeptide (SGP: sialylglycopeptide) extracted from a soluble fraction of chicken eggs.
- SGP sialylglycopeptide
- This SGP is a compound in which an asparagine residue of a peptide chain consisting of 6 amino acid residues is bound to the reducing end of a complex type sugar chain consisting of 11 sugar residues.
- SGP is, for example, based on the method of Seko et al. [Bioch em. Bioph ys. Ac ta, Volume 1335, Page 23 (1997)]. It has been shown that only about 8 mg can be obtained.
- Patent Document 1 International Publication No. W096 / 02255 (Claim 8 and Claim 10)
- An object of the present invention is to provide a method for producing a sugar chain asparagine derivative, which can obtain various isolated sugar chain asparagine derivatives useful in the field of pharmaceutical development and the like very easily and in large quantities. There is to do. '' Disclosure of the invention
- the present invention relates to the following inventions.
- a method for producing a sugar chain asparagine derivative from defatted egg yolk comprising: (a) a step of producing a glycated peptide mixture from defatted egg yolk with a proteolytic enzyme; and (b) a glycan peptide mixture comprising a peptide degrading enzyme. (C) a step of producing a sugar chain asparagine derivative mixture by introducing a lipophilic protecting group into the sugar chain asparagine in the sugar chain asparagine mixture, and (d) a step of producing a sugar chain asparagine derivative mixture.
- a method for producing a sugar chain asparagine derivative comprising a step of separating each sugar chain asparagine derivative by chromatography. 2. The method for producing the sugar chain asparagine derivative, wherein the defatted egg yolk is obtained by degreasing the egg yolk of an avian egg with an organic solvent.
- a process for producing the sugar chain asparagine derivative wherein the fat-soluble protecting group is a carbonate-containing group, an acyl group, an aryl group, an Fmo c group or a B oc group.
- a method for producing the sugar chain sparagin derivative wherein the sugar chain asparagine derivative contained in the sugar chain asparagine derivative mixture obtained in (c) is previously hydrolyzed to partially cleave sugar residues.
- a yolk for example, a defatted egg yolk obtained from avian egg yolk is obtained with a proteolytic enzyme, and then a mixture of sugar chain asparagine is obtained with a peptide degrading enzyme.
- a lipophilic protecting group is introduced (bonded) to the sugar chain asparagine contained in the mixture to obtain a mixture of sugar chain asparagine derivatives, and then the mixture is separated into each sugar chain asparagine derivative. It is a big feature.
- sucgar chain asparagine refers to a sugar chain in which asparagine is bound.
- “asparagine-linked glycan” is a group of sugar chains in which N-acetylyldarcosamine present at the reducing end is linked to the acid amino group of asparagine (A sn) in a protein polypeptide by N-glycoside. , Man (/ 3 1 -4) G lc Na c (1-4) Gc chain group with G 1 c N ac as the mother nucleus.
- “Sugar chain asparagine derivative” refers to a sugar chain asparagine in a state in which a lipophilic protecting group is bound to the asparagine residue.
- Ac HN represents a acetamido group.
- the production method of the sugar chain asparagine derivative of the present invention includes: (a) producing a glycopeptide mixture of defatted egg yolk with a proteolytic enzyme; and
- the production method for obtaining a sugar chain asparagine derivative from the defatted egg yolk of the present invention will be specifically described below.
- the defatted egg yolk used in the present invention is not particularly limited.
- egg yolks of birds eg, egg yolks such as chicken, quail, ducks, ducks, and pigeons are preferred
- human-type sugar chain asparagine especially human-type two-branched sugar chain asparagine
- organic solvent methanol, ethanol, jetyl ether and the like are preferable.
- the defatted egg yolk is cleaved with a proteolytic enzyme to obtain a mixture of sugar chain peptides (sugar chain paraffin peptide) contained in the defatted egg yolk.
- a proteolytic enzyme for example, general ones such as Pronase (manufactured by Wako Pure Chemical Industries), orientase (manufactured by HBI) can be used.
- components other than glycopeptides from a mixture of glycopeptides can be purified by known methods, for example, various chromatography using gel filtration columns, ion exchange columns, etc., and purification using high performance liquid chromatography (HPLC). Removal according to the method is preferred.
- HPLC high performance liquid chromatography
- step (b) the mixture of glycopeptides obtained in step (a) is used as peptide
- the peptide is decomposed with a degrading enzyme to obtain a mixture of sugar chain asparagine contained in the sugar chain peptide.
- a peptide degrading enzyme to be used for example, a general one such as a lactase can be used.
- components other than sugar chain asparagine can be obtained from a mixture of sugar chain asparagine by known methods, for example, various chromatographic methods using gel filtration columns, ion exchange columns, etc., and purification methods using high performance liquid chromatography (HPLC). Is preferably removed according to
- the hydrolysis method include a method using an acid and a method using an enzyme.
- the acid is not particularly limited.
- inorganic acids and organic acids such as hydrochloric acid, sulfuric acid, nitric acid, trifluoroacetic acid, cation exchange resins, insoluble solid reagents (silica gel, etc.) can be used. it can.
- the enzyme a sugar hydrolase is preferable, and an enzyme of any reaction type of endo type or exo type can be used.
- Such an enzyme is not particularly limited, and may be a commercially available enzyme, a newly isolated enzyme, or an enzyme created by genetic engineering as long as it has the activity.
- the enzyme reaction may be carried out in accordance with known conditions. In this case, the progress of the reaction may be traced with a thin layer chromatograph, and the reaction may be appropriately stopped when the most compound is obtained.
- step (c) the mixture containing the sugar chain asparagine obtained in step (b) is used, and a lipophilic protecting group is introduced into the sugar chain asparagine contained therein.
- the protective group is not particularly limited.
- a protecting group such as an acyl group such as a group, an aryl group, and a benzyl group can be used.
- the protecting group is preferably an F moc group or a B oc group widely used for peptide synthesis.
- the oc group is more preferable because it is particularly effective when sugars such as sialic acid that are unstable to relatively acidic conditions are present in the sugar chain.
- the protective group can be introduced by a known method (for example,
- the F moc group when using the F moc group, add a suitable amount of caseone or DMF to the mixture containing the sugar chain asparagine, and then add 9_fluorenylmethyl mono-N-succinimidyl carbonate and sodium bicarbonate.
- the F moc group can be introduced into the asparagine residue of the sugar chain wasparagine by dissolving and performing the F moc group binding reaction to the asparagine residue at 25.
- step (d) the sugar chain asparagine derivative mixture obtained in step (c) is subjected to known chromatography, particularly preparative chromatography, to separate each sugar chain asparagine derivative.
- the obtained sugar chain asparagine derivative mixture can be used directly, but from the viewpoint of efficiently obtaining a sugar chain asparagine derivative having a desired sugar chain structure, the mixture is further added to the mixture.
- a mixture of sugar chain asparagine derivatives obtained by subjecting the contained sugar chain asparagine derivative to hydrolysis and cleaving some sugar residues in advance may be used. The degree of sugar residue cleavage is the same as described above. Hydrolysis can be performed in the same manner as described above. Separation of each sugar chain asparagine derivative by chromatography can be appropriately carried out by using known kuguchimatography singly or in combination.
- the obtained sugar chain asparagine derivative mixture is purified by gel filtration power chromatography and then purified using HPLC.
- HPLC a reversed-phase column is suitable, for example, ODS, phenyl, nitrile, anion exchange column, specifically, for example, Mono Q manufactured by Pharmacia. Columns, Jiatron Iatobe beads columns, etc. can be used.
- the separation conditions and the like may be appropriately adjusted with reference to known conditions.
- sugar chain asparagine derivative obtained above examples include, for example, 11-5 sugar chain asparagine derivatives, preferably 11-7 sugar chain asparagine derivatives, more preferably 11-9 sugar chain asparagine derivatives, and particularly preferably the following formula: And 11 sugar chain paraffin derivatives represented by the formula: In the formula, P r o t represents a protecting group.
- a sugar chain asparagine derivative having a desired sugar chain structure can be efficiently obtained by hydrolyzing the separated sugar chain asparagine derivative.
- the kind of sugar chain asparagine derivative contained in the mixture is limited so that the sugar chain asparagine derivative is roughly separated, and then hydrolyzed, for example, by using a sugar hydrolase.
- a sugar chain asparagine derivative having a desired sugar chain structure can be obtained efficiently.
- the hydrolysis can be performed in the same manner as described above.
- each sugar chain asparagine derivative After obtaining each sugar chain asparagine derivative, the derivative is further hydrolyzed using various sugar hydrolases, etc., and the sugar residue at the non-reducing end of the sugar chain is removed, for example, sugar Various sugar chain asparagine derivatives having non-uniform branched structures at the chain ends can be obtained as single compounds.
- various sugar hydrolyzing enzymes and changing the order of hydrolysis and the type thereof more types of sugar chain asparagine derivatives can be produced.
- the present invention also provides a method for producing a sugar chain asparagine, which can obtain a large amount of various isolated sugar chain asparagines.
- the method includes a step of removing a protecting group from the obtained sugar chain asparagine derivative, following the production step of the sugar chain asparagine derivative according to the method for producing the sugar chain asparagine derivative.
- Removal of the protecting group from the sugar chain asparagine derivative can be carried out according to a known method (for example, Protecting Groups in Organic Chemistry, John Wiley & Sons INC., New York 1991, ISBN 0—471—62301— (See 6).
- the protecting group is an F moc group
- the F moc group can be removed by adding morpholine to a sugar chain asparagine derivative in N, N-dimethylformamide (DMF).
- the Boc group can be removed by reacting with a weak acid.
- a sugar chain asparagine is obtained by purifying by a known method, if necessary, by a known method, for example, various chromatography using a gel filtration column, an ion exchange column, etc., or a method of separation by HPLC. May be.
- the protecting group is a benzyl group
- the removal of the benzyl group can be performed according to a known method (for example, Protecting Groups in Organic Chemistry, John Wiley & Sons INC., New York). 1991, ISBN. 0—471— 62301—6).
- the removal of the asparagine residue from the sugar chain asparagine can be performed according to a known method.
- a sugar chain can be obtained by reacting sugar chain asparagine with anhydrous hydrazine and then acetylating it to remove the asparagine residue.
- the sugar chain can be obtained by removing the asparagine residue by heating and refluxing the sugar chain asparagine with a basic aqueous solution, followed by acetylation. After removing the asparagine residue, if necessary, it may be purified by a known method, for example, various types of chromatography using a gel filtration column, an ion exchange column, or a separation method using HPLC.
- a sugar chain asparagine derivative having a desired sugar chain structure, a sugar chain asparagine, and a sugar chain (hereinafter sometimes referred to as three sugar chains) are inexpensively and efficiently produced. Can be manufactured in large quantities.
- sugar chains are very useful in fields such as drug development.
- an example of application in pharmaceutical development is cancer vaccine synthesis. It is known that when cells become cancerous, sugar chains that were not found in the body are expressed. It is also known that when the sugar chain is chemically synthesized and administered to an individual as a vaccine, the growth of cancer is suppressed. Therefore, if a desired sugar chain can be produced according to the present invention, a vaccine effective for cancer treatment can be synthesized.
- the sugar chains obtained according to the present invention are further derivatized by combining a chemical reaction and a reaction with glycosyltransferase to bond a new sugar residue to synthesize a novel sugar chain. It is also possible.
- erythropoietin a glycoprotein
- EPO erythropoietin
- protein has sugar
- the present invention has a desired sugar chain structure in which only a large amount of protein is prepared by an E. coli expression system that cannot bind sugar chains, and then has a desired sugar chain structure.
- the desired sugar chain in the sugar chain asparagine obtained according to the present invention is bound to the N-acetylyldarcosamine residue using iS —N-acetylyldarcosaminidase (E ndo-M).
- E ndo-M N-acetylyldarcosamine residue
- N-acetylyldarcosamine is bound to tRNA, and a glycoprotein having an N-acetylyldarcosamine residue is synthesized using an expression system such as E. coli, and then obtained according to the present invention. It is also possible to introduce a desired sugar chain in the obtained sugar chain asparagine using Endo-M.
- glycoprotein As a therapeutic agent, the problem of using glycoprotein as a therapeutic agent is that the metabolic rate of the administered glycoprotein is high. This is because the glycoprotein is metabolized by the liver as soon as sialic acid present at the sugar chain end of the glycoprotein is removed in vivo. Therefore, it is necessary to administer a certain amount of glycoprotein. Therefore, by producing a sugar chain in which sialic acid that is difficult to be removed at the end of the sugar chain is newly incorporated according to the present invention and introducing the sugar chain into a target protein using Endo-M, in vivo It is possible to control the metabolic rate of glycoprotein Thus, it is possible to reduce the amount of glycoprotein to be administered.
- One egg yolk was introduced into the stirring place of ethanol (E tOH) 67m1. After stirring for about 5 hours, filtration was performed, and further washing was performed with 30 ml of EtOH. Add 83 ml of Et OH again to the obtained crystals, stir 1 ⁇ , filter, wash with 30 ml of Et OH, and dry the crystals to obtain about 3 delipidated egg yolk (De lipidated Egg Yo 1 k). g was obtained.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Materials Engineering (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Saccharide Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04707645.0A EP1591532B1 (en) | 2003-02-04 | 2004-02-03 | Process for producing sugar chain asparagine derivative |
US10/544,212 US7955819B2 (en) | 2003-02-04 | 2004-02-03 | Process for producing sugar chain asparagine derivative |
CA2514337A CA2514337C (en) | 2003-02-04 | 2004-02-03 | Process for producing sugar chain asparagine derivative |
AU2004209371A AU2004209371B2 (en) | 2003-02-04 | 2004-02-03 | Process for producing sugar chain asparagine derivative |
JP2005504829A JP4237752B2 (ja) | 2003-02-04 | 2004-02-03 | 糖鎖アスパラギン誘導体の製造方法 |
DK04707645.0T DK1591532T3 (en) | 2003-02-04 | 2004-02-03 | PROCEDURE FOR PREPARING ASPARAGIN DERIVATIVES WITH SUGAR CHAIN |
ES04707645T ES2701175T3 (es) | 2003-02-04 | 2004-02-03 | Proceso para producir derivado de asparagina de cadena de azúcar |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003026609 | 2003-02-04 | ||
JP2003-26609 | 2003-02-04 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004070046A1 true WO2004070046A1 (ja) | 2004-08-19 |
WO2004070046A8 WO2004070046A8 (ja) | 2005-08-25 |
Family
ID=32844148
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/001048 WO2004070046A1 (ja) | 2003-02-04 | 2004-02-03 | 糖鎖アスパラギン誘導体の製造方法 |
Country Status (14)
Country | Link |
---|---|
US (1) | US7955819B2 (ja) |
EP (2) | EP1591532B1 (ja) |
JP (1) | JP4237752B2 (ja) |
KR (1) | KR20050095609A (ja) |
CN (1) | CN100378225C (ja) |
AU (1) | AU2004209371B2 (ja) |
CA (1) | CA2514337C (ja) |
DK (1) | DK1591532T3 (ja) |
ES (1) | ES2701175T3 (ja) |
HU (1) | HUE041502T2 (ja) |
PT (1) | PT1591532T (ja) |
TR (1) | TR201820053T4 (ja) |
TW (1) | TWI344819B (ja) |
WO (1) | WO2004070046A1 (ja) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007153787A (ja) * | 2005-12-02 | 2007-06-21 | Otsuka Chemical Co Ltd | 糖鎖修飾リポソーム |
WO2009017154A1 (ja) | 2007-07-31 | 2009-02-05 | Otsuka Chemical Co., Ltd. | ペプチドの製造方法 |
WO2009153960A1 (ja) | 2008-06-17 | 2009-12-23 | 大塚化学株式会社 | 糖鎖付加glp-1ペプチド |
WO2010021126A1 (ja) | 2008-08-19 | 2010-02-25 | 大塚化学株式会社 | 糖タンパク質の製造方法及びスクリーニング方法 |
WO2010092943A1 (ja) | 2009-02-10 | 2010-08-19 | 大塚化学株式会社 | IgG-Fcフラグメント及びその製造方法 |
WO2011007747A1 (ja) | 2009-07-16 | 2011-01-20 | 大塚化学株式会社 | 糖鎖付加ailim細胞外ドメイン及びその製造方法 |
WO2011027868A1 (ja) * | 2009-09-03 | 2011-03-10 | 公益財団法人野口研究所 | 11糖シアリルオリゴ糖ペプチドの製造方法 |
WO2011052523A1 (ja) | 2009-10-30 | 2011-05-05 | 大塚化学株式会社 | 抗原性glp-1アナログの糖鎖付加体 |
JP2011231293A (ja) * | 2010-04-30 | 2011-11-17 | Asahi Kasei Corp | 糖ペプチド誘導体及びその製造方法 |
WO2012121206A1 (ja) | 2011-03-10 | 2012-09-13 | 株式会社糖鎖工学研究所 | シアリル糖鎖を有する糖ペプチドの製造方法、当該製造方法に使用するシアリル糖鎖付加アミノ酸誘導体、及び当該糖ペプチド |
JP2012191932A (ja) * | 2011-03-03 | 2012-10-11 | Asahi Kasei Corp | 11糖シアリルオリゴ糖アスパラギンの製造方法 |
WO2013032011A1 (ja) | 2011-09-04 | 2013-03-07 | 株式会社糖鎖工学研究所 | 糖鎖付加ポリペプチドおよび当該ポリペプチドを含む医薬組成物 |
WO2013032012A1 (ja) | 2011-09-04 | 2013-03-07 | 株式会社糖鎖工学研究所 | 糖鎖付加ポリペプチドおよび当該ポリペプチドを含む医薬組成物 |
WO2014080730A1 (ja) | 2012-11-22 | 2014-05-30 | 株式会社糖鎖工学研究所 | 糖鎖付加リンカー、糖鎖付加リンカー部分と生理活性物質部分とを含む化合物またはその塩、及びそれらの製造方法 |
WO2014084110A1 (ja) | 2012-11-30 | 2014-06-05 | 株式会社糖鎖工学研究所 | 糖鎖付加リンカー、糖鎖付加リンカーと生理活性物質とを含む化合物またはその塩、及びそれらの製造方法 |
WO2014162906A1 (ja) | 2013-03-30 | 2014-10-09 | 株式会社糖鎖工学研究所 | 糖鎖-ポリペプチド複合体 |
WO2023157924A1 (ja) * | 2022-02-18 | 2023-08-24 | Khネオケム株式会社 | 複合型糖アスパラギン及びその製造方法 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2668163C2 (ru) | 2013-03-29 | 2018-09-26 | Глитек, Инк. | Полипептид, гликозилированный сиалилированной сахарной цепью |
CN113121718B (zh) * | 2021-05-13 | 2022-09-23 | 东南大学 | 一种迷果芹多糖psgp-2及其制备方法与应用 |
WO2022255289A1 (ja) | 2021-05-31 | 2022-12-08 | Khネオケム株式会社 | 糖ぺプチドを製造する方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003000843A2 (en) * | 2001-06-20 | 2003-01-03 | The Brigham And Women's Hospital, Inc. | P53 binding protein-related protein in cardiomyopathy |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3930559B2 (ja) | 1994-07-15 | 2007-06-13 | 太陽化学株式会社 | シアル酸誘導体を含有する医薬組成物 |
JPH0899988A (ja) * | 1994-09-29 | 1996-04-16 | Takehiko Yamamoto | シアル酸類含有オリゴ糖の製造法 |
AU2002346294B2 (en) * | 2001-06-19 | 2006-08-17 | Glytech, Inc. | Process for producing sugar chain asparagine derivative |
-
2004
- 2004-02-03 HU HUE04707645A patent/HUE041502T2/hu unknown
- 2004-02-03 ES ES04707645T patent/ES2701175T3/es not_active Expired - Lifetime
- 2004-02-03 CA CA2514337A patent/CA2514337C/en not_active Expired - Fee Related
- 2004-02-03 AU AU2004209371A patent/AU2004209371B2/en not_active Expired
- 2004-02-03 EP EP04707645.0A patent/EP1591532B1/en not_active Expired - Lifetime
- 2004-02-03 PT PT04707645T patent/PT1591532T/pt unknown
- 2004-02-03 DK DK04707645.0T patent/DK1591532T3/en active
- 2004-02-03 KR KR1020057012948A patent/KR20050095609A/ko not_active Application Discontinuation
- 2004-02-03 TW TW093102374A patent/TWI344819B/zh not_active IP Right Cessation
- 2004-02-03 US US10/544,212 patent/US7955819B2/en active Active
- 2004-02-03 TR TR2018/20053T patent/TR201820053T4/tr unknown
- 2004-02-03 CN CNB2004800035452A patent/CN100378225C/zh not_active Expired - Lifetime
- 2004-02-03 WO PCT/JP2004/001048 patent/WO2004070046A1/ja active Application Filing
- 2004-02-03 JP JP2005504829A patent/JP4237752B2/ja not_active Expired - Lifetime
- 2004-02-03 EP EP13167297.4A patent/EP2626429A1/en not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003000843A2 (en) * | 2001-06-20 | 2003-01-03 | The Brigham And Women's Hospital, Inc. | P53 binding protein-related protein in cardiomyopathy |
Non-Patent Citations (1)
Title |
---|
INAZU T. ET AL: "Preparation of Fmoc-asparagine derivatives having natural N-linked oligosaccharide, and its application to the synthesis of glycopeptides", PEPTIDE SCIENCE, vol. 1998, 1999, pages 153 - 156, XP002977698 * |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007153787A (ja) * | 2005-12-02 | 2007-06-21 | Otsuka Chemical Co Ltd | 糖鎖修飾リポソーム |
WO2009017154A1 (ja) | 2007-07-31 | 2009-02-05 | Otsuka Chemical Co., Ltd. | ペプチドの製造方法 |
US8809258B2 (en) | 2007-07-31 | 2014-08-19 | Glytech, Inc. | Method for producing peptide |
EP2767545A1 (en) | 2007-07-31 | 2014-08-20 | Glytech, Inc. | Method for producing peptide |
WO2009153960A1 (ja) | 2008-06-17 | 2009-12-23 | 大塚化学株式会社 | 糖鎖付加glp-1ペプチド |
WO2010021126A1 (ja) | 2008-08-19 | 2010-02-25 | 大塚化学株式会社 | 糖タンパク質の製造方法及びスクリーニング方法 |
WO2010092943A1 (ja) | 2009-02-10 | 2010-08-19 | 大塚化学株式会社 | IgG-Fcフラグメント及びその製造方法 |
WO2011007747A1 (ja) | 2009-07-16 | 2011-01-20 | 大塚化学株式会社 | 糖鎖付加ailim細胞外ドメイン及びその製造方法 |
WO2011027868A1 (ja) * | 2009-09-03 | 2011-03-10 | 公益財団法人野口研究所 | 11糖シアリルオリゴ糖ペプチドの製造方法 |
JP2011162762A (ja) * | 2009-09-03 | 2011-08-25 | Asahi Kasei Corp | 11糖シアリルオリゴ糖ペプチドの製造方法 |
US8809496B2 (en) | 2009-09-03 | 2014-08-19 | The Noguchi Institute | Production method of 11-sugar sialylglycopeptide |
WO2011052523A1 (ja) | 2009-10-30 | 2011-05-05 | 大塚化学株式会社 | 抗原性glp-1アナログの糖鎖付加体 |
JP2011231293A (ja) * | 2010-04-30 | 2011-11-17 | Asahi Kasei Corp | 糖ペプチド誘導体及びその製造方法 |
JP2012191932A (ja) * | 2011-03-03 | 2012-10-11 | Asahi Kasei Corp | 11糖シアリルオリゴ糖アスパラギンの製造方法 |
WO2012121206A1 (ja) | 2011-03-10 | 2012-09-13 | 株式会社糖鎖工学研究所 | シアリル糖鎖を有する糖ペプチドの製造方法、当該製造方法に使用するシアリル糖鎖付加アミノ酸誘導体、及び当該糖ペプチド |
WO2013032012A1 (ja) | 2011-09-04 | 2013-03-07 | 株式会社糖鎖工学研究所 | 糖鎖付加ポリペプチドおよび当該ポリペプチドを含む医薬組成物 |
WO2013032011A1 (ja) | 2011-09-04 | 2013-03-07 | 株式会社糖鎖工学研究所 | 糖鎖付加ポリペプチドおよび当該ポリペプチドを含む医薬組成物 |
WO2014080730A1 (ja) | 2012-11-22 | 2014-05-30 | 株式会社糖鎖工学研究所 | 糖鎖付加リンカー、糖鎖付加リンカー部分と生理活性物質部分とを含む化合物またはその塩、及びそれらの製造方法 |
WO2014084110A1 (ja) | 2012-11-30 | 2014-06-05 | 株式会社糖鎖工学研究所 | 糖鎖付加リンカー、糖鎖付加リンカーと生理活性物質とを含む化合物またはその塩、及びそれらの製造方法 |
WO2014162906A1 (ja) | 2013-03-30 | 2014-10-09 | 株式会社糖鎖工学研究所 | 糖鎖-ポリペプチド複合体 |
WO2023157924A1 (ja) * | 2022-02-18 | 2023-08-24 | Khネオケム株式会社 | 複合型糖アスパラギン及びその製造方法 |
Also Published As
Publication number | Publication date |
---|---|
JP4237752B2 (ja) | 2009-03-11 |
WO2004070046A8 (ja) | 2005-08-25 |
CA2514337C (en) | 2010-07-13 |
TR201820053T4 (tr) | 2019-01-21 |
KR20050095609A (ko) | 2005-09-29 |
TW200420231A (en) | 2004-10-16 |
CN100378225C (zh) | 2008-04-02 |
CA2514337A1 (en) | 2004-08-19 |
EP2626429A1 (en) | 2013-08-14 |
CN1777679A (zh) | 2006-05-24 |
US7955819B2 (en) | 2011-06-07 |
TWI344819B (en) | 2011-07-11 |
DK1591532T3 (en) | 2019-01-21 |
US20060205039A1 (en) | 2006-09-14 |
JPWO2004070046A1 (ja) | 2006-05-25 |
ES2701175T3 (es) | 2019-02-21 |
EP1591532B1 (en) | 2018-10-31 |
EP1591532A4 (en) | 2011-03-30 |
HUE041502T2 (hu) | 2019-05-28 |
EP1591532A1 (en) | 2005-11-02 |
PT1591532T (pt) | 2019-01-11 |
AU2004209371A1 (en) | 2004-08-19 |
AU2004209371B2 (en) | 2008-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004070046A1 (ja) | 糖鎖アスパラギン誘導体の製造方法 | |
JP4323139B2 (ja) | 糖鎖アスパラギン誘導体の製造方法 | |
JP5345118B2 (ja) | 3分岐型糖鎖アスパラギン誘導体、該糖鎖アスパラギン、該糖鎖およびそれらの製造方法 | |
KR100736510B1 (ko) | 당사슬 아스파라긴 유도체, 당사슬 아스파라긴, 당사슬 및그들의 제조법 | |
JP4607017B2 (ja) | アミノ化複合型糖鎖誘導体及びその製造方法 | |
WO2004058789A9 (ja) | 糖鎖アスパラギン誘導体およびその製造方法 | |
Xue et al. | Efficient synthesis of complex glycopeptides based on unprotected oligosaccharides | |
TWI324607B (ja) | ||
JP2006022191A (ja) | 3分岐型糖鎖アスパラギン誘導体、該糖鎖アスパラギン、該糖鎖およびそれらの製造方法 | |
AU2006203198B2 (en) | Sugar chain asparagine derivative | |
JPH10248590A (ja) | グリコシルアスパラギン誘導体の製造法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005504829 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020057012948 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004209371 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004707645 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10544212 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2514337 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20048035452 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 2004209371 Country of ref document: AU Date of ref document: 20040203 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004209371 Country of ref document: AU |
|
CFP | Corrected version of a pamphlet front page |
Free format text: UNDER (72, 75) THE TRANSLITERATION IN JAPANESE OF THE NAME OF "FUKAE, KAZUHIRO" CORRECTED |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057012948 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2004707645 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10544212 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10598251 Country of ref document: US |